Ziprasidone-Induced galactorrhea in an adolescent female: A case report

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 12, Issue 3, 2010, Pages

  Raza, Shakeel ^a   Haq, Fasiha ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; FLUOXETINE; PROLACTIN; QUETIAPINE; VALPROATE SEMISODIUM; ZIPRASIDONE;

ACTING OUT; ADOLESCENT; ANGER; ATTENTION DEFICIT DISORDER; AUDITORY HALLUCINATION; AUTOMUTILATION; AVOIDANCE BEHAVIOR; BIPOLAR DISORDER; CASE REPORT; DRUG WITHDRAWAL; DYSPHORIA; FEMALE; GALACTORRHEA; HUMAN; HYPERACTIVITY; HYPERPROLACTINEMIA; IMPULSIVENESS; LETTER; MOOD CHANGE; NIGHTMARE; OPPOSITIONAL DEFIANT DISORDER; PARANOIA; POSTTRAUMATIC STRESS DISORDER; PROLACTIN BLOOD LEVEL; PSYCHOSIS;

EID: 78650554462     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.09l00855gry     Document Type: Letter

References (15)

1. Petty RG. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res. 1999;35(suppl):S67-S73. PubMed doi:10.1016/S0920-9964(98)00158-3
2. Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol. 1999;19(1):57-61. PubMed doi:10.1097/00004714-199902000-00011
3. Maguire GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry. 2002;63(suppl 4):56-62. PubMed
4. Bench CJ, Lammertsma AA, Grasby PM, et al. The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography. Psychopharmacology (Berl). 1996;124(1-2):141-147. PubMed doi:10.1007/BF02245614
5. Miceli JJ, Wilner KD, Hansen RA, et al. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Br J Clin Pharmacol. 2000;49(suppl 1):5S-13S. PubMed doi:10.1046/j.1365-2125.2000.00147.x
6. Smith S. Effects of antipsychotics on sexual and endocrine function in women: implications for clinical practice. J Clin Psychopharmacol. 2003;23(suppl 1):S27-S32. PubMed doi:10.1097/00004714-200306001-00006
7. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47(1):27-38. PubMed
8. Addington DE, Pantelis C, Dineen M, et al. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry. 2004;65(12):1624-1633. PubMed doi:10.4088/JCP.v65n1207
9. Saldaña SN, Delgado SV. Ziprasidone-associated galactorrhea in an adolescent female. J Child Adolesc Psychopharmacol. 2007;17(2):259-260. PubMed doi:10.1089/cap.2006.0053
10. Ramadan M, Khan A, Preskorn S. D2-blockade and possible ziprasidone-induced galactorrhea. Int Clin Psychopharmacol. 2005;20(2):113-114. PubMed doi:10.1097/00004850-200503000-00009
11. Kopecek M, Bares M, Mohr P. Ziprasidone-induced galactorrhea: a case report. Neuroendocrinol Lett. 2005;26(1):69-70. PubMed
12. Lusskin SI, Cancro R, Chuang L, et al. Prolactin elevation with ziprasidone. Am J Psychiatry. 2004;161(10):1925. PubMed doi:10.1176/appi.ajp.161.10.1925
13. Jordan MP. Ziprasidone-associated galactorrhea in a female teenager. J Am Acad Child Adolesc Psychiatry. 2003;42(1):4-5. PubMed doi:10.1097/00004583-200301000-00004
14. Young RM, Lawford BR, Barnes M, et al. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br J Psychiatry. 2004;185(2):147-151. PubMed doi:10.1192/bjp.185.2.147
15. Roose SP, Pollock BG, Devanand DP. Treatment during late life. In: Schatzberg AF, Nemeroff CB, eds. Essentials of Clinical Psychopharmacology. 2nd ed. Arlington, VA: American Psychiatric Publishing, Inc; 2007.